4/2
08:11 am
mlys
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its price target raised by analysts at HC Wainwright from $30.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its price target raised by analysts at HC Wainwright from $30.00 to $42.00. They now have a "buy" rating on the stock.
3/29
02:46 pm
mlys
New blood pressure drug helps people with uncontrolled hypertension in trial [CNBC]
Medium
Report
New blood pressure drug helps people with uncontrolled hypertension in trial [CNBC]
3/29
02:30 pm
mlys
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
Medium
Report
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
3/25
08:00 am
mlys
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Low
Report
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
3/18
04:01 pm
mlys
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Medium
Report
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
3/17
08:07 am
mlys
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo [Yah
Low
Report
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo [Yah
3/17
08:00 am
mlys
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
Low
Report
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
3/11
10:20 pm
mlys
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
Medium
Report
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
3/10
04:06 pm
mlys
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
3/10
04:01 pm
mlys
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Low
Report
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
3/10
01:15 pm
mlys
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
3/10
07:07 am
mlys
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension [Yahoo! Finance]
High
Report
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension [Yahoo! Finance]
3/10
07:00 am
mlys
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
High
Report
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
3/7
04:36 pm
mlys
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET [Yahoo! Finance]
High
Report
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET [Yahoo! Finance]
3/7
04:01 pm
mlys
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
High
Report
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
2/24
10:19 am
mlys
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at Guggenheim.
Low
Report
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at Guggenheim.
2/13
12:40 pm
mlys
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $28.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $28.00 to $24.00. They now have a "buy" rating on the stock.
2/13
08:10 am
mlys
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
2/12
09:09 am
mlys
Mineralys Therapeutics reports Q4 results [Seeking Alpha]
Low
Report
Mineralys Therapeutics reports Q4 results [Seeking Alpha]
2/12
07:00 am
mlys
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2/5
04:05 pm
mlys
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
Low
Report
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
2/4
08:50 am
mlys
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria [Yahoo! Finance]
Low
Report
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria [Yahoo! Finance]
2/4
08:00 am
mlys
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Low
Report
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
1/19
08:20 pm
mlys
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension [Seeking Alpha]
Medium
Report
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension [Seeking Alpha]